Overview
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Status:
No longer available
No longer available
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.Details
Lead Sponsor:
Eisai Inc.Treatments:
Denileukin diftitox
Interleukin-2
Criteria
Inclusion Criteria:To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must
request this therapy for the specific patient. Patients may continue treatment with
denileukin diftitox if they:
- Are currently on therapy with denileukin diftitox and require ongoing therapy to
maintain control of their disease.
- Are willing and able to comply with all aspects of the Access Protocol
- Provide written informed consent to participate
Exclusion Criteria:
Patients are not eligible for the Access Program with denileukin diftitox if they:
• Are not currently on denileukin diftitox therapy